Stardom Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 14 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 351.84%
- Profit Growth 434.59%
- Ebitda 318.27%
- Net Worth 37.80%
- Total Assets 70.91%
About Stardom Pharmaceuticals
Stardom Pharmaceuticals Private Limited (SPPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 December 2010 and has a history of 14 years and one month. Its registered office is in New Delhi, Delhi, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Madhu Sharma, Nikhil Kumar, and Kaushal Mishra serve as directors at the Company.
Company Details
-
Location
New Delhi, Delhi, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232DL2010PTC211417
-
Company No.
211417
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
14 Dec 2010
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Stardom Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Madhu Sharma
|
Director | 03-Dec-2021 | Current |
| Nikhil Kumar | Additional Director | 28-Jun-2024 | Current |
| Kaushal Mishra | Additional Director | 28-Jun-2024 | Current |
Financial Performance of Stardom Pharmaceuticals.
Stardom Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 351.84% increase. The company also saw a substantial improvement in profitability, with a 434.59% increase in profit. The company's net worth Soared by an impressive increase of 37.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Stardom Pharmaceuticals?
In 2023, Stardom Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Stardom Pharmaceuticals?
Unlock and access historical data on people associated with Stardom Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Stardom Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Stardom Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
